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Abstract
Introduction: A portion of patients with head and neck cancer (HNC)-
associated pain may not experience relief in symptoms with non-invasive 
modalities. A nerve block is a procedure in which a local anaesthetic agent 
is injected along the nerve track to preferentially block sensory transmission. 
The literature on the effectiveness of nerve blocks in the management of 
HNC-related pain is limited. The purpose of this study was to determine 
the effectiveness of nerve blocks in the management of breakthrough 
HNC-associated trigeminal or cervical neuropathic pain disorders. 
Materials and Methods: A retrospective chart review of patients who 
underwent a nerve block or infiltration procedure in the regions of head 
and neck for the management of breakthrough HNC-associated trigeminal 
or cervical neuropathic pain disorders in the Orofacial Pain Medicine 
Clinic, Shaukat Khanum Memorial Cancer Hospital and Research Centre, 
between November 2018 and November 2019 was completed. Information 
regarding demographics, diagnosis and pain characteristics was extracted 
and reviewed. The Fisher’s exact test and Mann–Whitney U-test were used 
for analysis between independent and dependent variables. Results: A total 
of 27 participants were included in the investigation, of which 66.7% were 
male. The average pre-procedure pain score was 6.85±2.54. Following 
intervention, 81.5% of the participants experienced >75% relief in pain for 
longer than 48 hours. The mean immediate post-procedure pain score was 
0.26±1.02 and the average duration of relief was 6.10±6.50 weeks. The 
significant effect of nerve blocks was found to be statistically associated with 
the concurrent use of amitriptyline (P = 0.017).  Conclusion: Nerve blocks, as 
an adjunctive therapy to pharmacologic treatment, can provide significant 
relief to patients with breakthrough HNC-associated trigeminal and cervical 
neuropathic pain disorders. However, the duration of relief experienced by 
the participants is inconsistent. The beneficial effect of nerve blocks appears 
to be more common in patients that were concurrently using amitriptyline.
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Introduction
Pain is a common symptom associated with 
cancer and its treatment. The overall prevalence 
of cancer-related pain ranges from 40% to 60%. 
Among various cancer types, the prevalence 
of pain in head and neck cancers (HNCs) is the 
highest, with estimates up to 86%.[1] This is likely 
due to the erosive and aggressive nature of the 
disease process as well as the extensive and rich 
nerve supply of the craniofacial region. Similarly, 
complex functional and parafunctional jaw and 
cervical movements may cause dynamic pain.[2,3]
The management of cancer-related pain primarily 
consists of disease-modifying treatments (surgery, 
radiation therapy and chemotherapy) and 
pharmacotherapy. Other options include non-
pharmacological interventions, such as physical 
and occupational therapy and behavioural pain 
management. Altogether, these modalities can 
help in improving pain control and reducing pain-
associated disability and distress.[4,5] Nonetheless, 
in 10–20% of HNC-related pain cases, pain 
may become refractory and not resolve with 
conventional measures.[6] Such patients may find 
relief from interventional modalities, such as 
peripheral nerve infiltration or blocks or neurolysis 
procedures.[4,6,7]
A nerve infiltration or block is a procedure in which 
a local anaesthetic agent is injected along the 
nerve track to preferentially block sensory nerves. 
Local anaesthetics reversibly inhibit voltage-gated 
sodium channels, thereby impairing conduction 
through sensory nerve fibres.[8-10] The extent and 
duration of the block depend on various factors, 
such as the dose and pharmacokinetic properties 
of the anaesthetic, the characteristics of the 
nerve being anaesthetised such as thickness and 
myelination and the physiological and anatomical 
properties of the site of injection.[8,9]
Nerve blocks have previously been shown to 
be helpful in the management of refractory or 
breakthrough episodes of pain for various headache 
disorders and neuropathic pain conditions.[6,10-15] 
However, there are a limited number of studies 
on the effectiveness of nerve blocks in the 
management of HNC-related pain. The aim of this 
study was to determine the effectiveness of nerve 
blocks in the management of breakthrough HNC-
associated trigeminal or cervical neuropathic pain 
disorders.
Materials and Methods
Participants, study design and clinical setting
A retrospective chart review of patients who 
underwent a nerve block or infiltration procedure 
in the regions of the head and neck for the 
management of breakthrough HNC-associated 
trigeminal or cervical neuropathic pain disorders in 
the Orofacial Pain Medicine Clinic, Shaukat Khanum 
Memorial Cancer Hospital and Research Centre, 
between November 2018 and November 2019 was 
performed. Approval from the Institutional Research 
Ethics Committee was obtained (EX-23-12-19-01).
The diagnosis of HNC-associated trigeminal 
or cervical neuropathic pain was based on the 
International Headache Society diagnostic criteria 
for headache attributed to intracranial neoplasm 
and the International Classification of Orofacial Pain 
diagnostic criteria for trigeminal neuropathic pain 
attributed to other disorders[16,17] [Table 1].
Before treatment with a nerve block, all participants 
received at least three concurrent classes of 
medications, consisting of an opioid analgesic, 
either a tricyclic antidepressant or gabapentinoids 
(gabapentin or pregabalin) and either paracetamol 
or non-steroidal anti-inflammatory medication for 
the management of HNC-associated pain, as per 
ESMO clinical practice guidelines.[18] Participants 
were considered to have breakthrough pain if the 
use of these medications failed to alleviate the 
baseline pain of the patient by 50% for the entire 
intended duration between two consecutive doses 
of medications.
All adult male and female patients who had 
undergone a nerve block procedure in the 
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head and neck region for the management of 
breakthrough HNC-associated neuropathic pain 
were included in the investigation. HNCs were 
defined as carcinoma involving oral, oropharyngeal 
and nasopharyngeal regions, salivary glands, nasal 
cavity and paranasal sinus region and laryngeal 
and hypopharyngeal area. Excluded patients 
were those who underwent a chemical neurolysis 
procedure before the termination of anaesthetic 
or therapeutic response of the nerve blocks and 
patients that had nerve blocks for non-cancer or 
non-neuropathic pain disorders.
Clinical information
Medical charts were reviewed to collect data 
regarding patient demographics, cancer type 
and stage, primary site of disease, occurrence of 
metastasis, prior anti-cancer therapies (surgery, 
radiation therapy and chemotherapy), concurrent 
anti-cancer therapies (radiation therapy and 
chemotherapy) and medical history. The concurrent 
use of analgesics and adjuvant medications 
(muscle relaxants, antidepressants or neuropathic 
medications), irrespective of indication of use, 
was documented. Data regarding the pain score 
before and immediately after the administration 
of injections and at each patient encounter were 
noted. Patients rated their pain score on an 11-point 
Likert-type numeric verbal pain rating scale, in 
which 0 was indicative of no pain and 10 indicated 
their worst pain experience ever. Furthermore, 
information regarding the characteristics of pain 
(e.g., location, laterality, chronicity, frequency, 
quality and modifying factors) was documented. 
Information regarding the nerve(s) blocked and the 
type of anaesthetic agent used was noted.
Protocol of nerve blocks
Participants underwent a nerve block of at least 
one of the following nerves: Auriculotemporal 
nerve, mental nerve, inferior alveolar nerve, 
sphenopalatine ganglion, infraorbital nerve, 
superior alveolar nerves, supraorbital nerve, 
greater auricular nerve, greater and lesser 
occipital nerve and superficial cervical nerve 
plexus (C2–C4). The landmark technique was used 
for the administration of injections.[7,9] Inferior 
alveolar nerve, mental nerve and infraorbital 
nerve injections were performed using an intraoral 
approach. Conversely, for rest of the injections, an 
extraoral approach was used. Patients received 
either lidocaine 2% with epinephrine (1:100,000) or 
bupivacaine 0.5% without epinephrine. The choice 
of anaesthetic agent was based on the availability 
of instruments and the anaesthetic agent. The site 
and the severity of the patient’s pain directed the 
location, type and number of nerve blocks.
Response to nerve blocks
The response of participants to nerve blocks was 
considered to be significant, if the intervention 
resulted in at least 75% or more reduction in pre-
procedure pain, for at least 48 hours. The half-life of 
lignocaine 2% (with epinephrine) is estimated to be 
Table 1: Diagnostic criteria for HNC-associated 
trigeminal or cervical neuropathic pain disorder, 
based on the ICOP criteria for trigeminal 
neuropathic pain attributed to other disorders, 
and ICHD-3 criteria for headache attributed to 
intracranial neoplasm
A.  Pain, in neuroanatomically plausible area within the 
distribution(s) of one or both trigeminal or cervical 
nerve(s), persisting or recurring for >3 months and 
fulfilling criteria C and D
B.  Neoplasm of the head-and-neck area has been identi-
fied
C.  Evidence of causation demonstrated by one or more of 
the following:
1.  Pain has developed in temporal relation to the HNC or 
led to its discovery
2.  Pain has significantly worsened in parallel with wors-
ening of the HNC
D.  Pain is associated with somatosensory symptoms and/
or signs* in the same neuroanatomically plausible 
distribution
E.  Not better accounted for by another ICOP or ICHD-3 
diagnosis
*Somatosensory symptoms or signs may be negative (e.g., hy-
paesthesia and/or hypoalgesia) and/or positive (e.g., hyperalgesia 
and/or allodynia). HNC: Head-and-neck cancer, ICOP: International 
Classification of Orofacial Pain Disorders, ICHD-3: International 
Classification of Headache Disorders-3
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Nearly 85% of the participants had squamous 
cell carcinoma, with the primary tumour site 
most commonly being the alveolar mucosa of 
the maxillary or mandibular region (40.7%). All 
of the participants had Stage IV disease, and in 
approximately 60% of the participants, there was 
evidence of disease metastasis. Almost half of the 
participants had undergone surgical intervention 
for the management of cancer, and nearly 89% 
of the participants had a history of undergoing 
radiation therapy and chemotherapy. At the time 
of intervention, nearly half of the participants were 
actively undergoing chemotherapy. The most 
common medical comorbidity was hypertension 
(14.8%) and ischaemic heart disease (11.1%).
The average pre-procedure pain score was 
6.85±2.54. In 81.5% of the participants, pain 
originated from the tumour alone, whereas the 
remaining 18.5% had pain originating secondary 
around 1.5–2 hours and the half-life of bupivacaine 
0.5% (without epinephrine) is approximately 
3.5 hours. A benchmark of 48 hours was utilised 
as it allows the anaesthetic effects of either of the 
two local anaesthetic agents to have resolved by 
this time period, and the analgesic response of 
the blocks would be evidently appreciable. The 
duration of relief in pain was reported in terms of 
number of weeks. This information was extracted 
from the subsequent visits of the patients to the 
Orofacial Pain Medicine Clinic. Participants who 
did not report for a follow-up visit after the injection 
therapy were considered to have no or minimal 
relief in symptoms for the purpose of the analysis.
Statistical analysis
The statistical analysis was performed using 
SPSS software (version 22.0; SPSS, Chicago, IL). 
Descriptive statistics were computed for each 
variable. If any study variable was missing for 
the included participants, it was excluded in the 
statistical analysis. The Fisher’s exact test and Mann–
Whitney U-test were used for analysis between 
independent and dependent variables. P < 0.05 
was considered as statistically significant.
Results
A total of 84 charts were identified and reviewed. 
Twenty-seven participants who underwent at 
least one nerve block for the management of 
breakthrough pain related to HNC-associated 
trigeminal or cervical neuropathic pain disorder 
were included in this investigation. Fifty-seven 
participants were excluded for either undergoing 
neurolysis procedure immediately after the nerve 
block or because they had nerve block for the 
management of non-cancerous or non-neuropathic 
pain disorder. Among the participants included, 
a total of 43 nerves were blocked. For the 27 
participants included in the analysis, there were 
no missing data.
Patient characteristics are reviewed in Table 2. Of 
the 27 participants, 18 (66.7%) were male. The 
average age of the cohort was 44.44±12.97 years. 
Table 2: Summary of demographic and diagnostic 





Age (years) Mean 44.44±12.97
Gender Male 66.7% (18)



















Alveolar mucosa 40.7% (11)
Tongue 18.5% (5)
Buccal mucosa 14.8% (4)
Parotid gland 14.8% (4)
Other (nasopha-
ryngeal, external 
auditory canal and 
hard palate)
22.2% (6)
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to the tumour and as a toxicity of their cancer 
treatment. The pain was unilateral in almost 70% 
of the participants, and the most common sites of 
pain were along the distribution of mandibular 
division of trigeminal nerve (63%) and cervical 
nerves (C2-C4) (59.3%). Furthermore, nearly 40% of 
the participants had pain along at least two or more 
divisions. The most common descriptors of pain 
reported by the participants were burning (59.3%), 
dull ache (59.3%) and stabbing (59.3%) [Table 3].
At the time of intervention, participants were 
concurrently using paracetamol (88.9%), 
nonsteroidal anti-inflammatory drugs (63%), 
tricyclic antidepressants (70.4%), muscle relaxants 
(44.4%), gabapentinoids (74.1%) and opioids 
(100%).
After undergoing the nerve block procedure, 
81.5% of the participants had more than 75% 
relief in pain for longer than 48 hours. The mean 
immediate post-procedure pain score was 
0.26±1.02. The average duration of relief that 
was experienced by the participants following 
intervention was 6.10±6.50 weeks. Among these, 
74% of the participants had relief for 1 week or 
more, and almost 59% of the participants had 
relief for 1 month or more [Table 4]. The most 
anaesthetised nerves were the inferior alveolar 
nerve (40.7%), superior cervical plexus (37%) and 
auriculotemporal nerve (29.6%).
The beneficial effect of nerve blocks was found 
to be statistically associated with the concurrent 
use of amitriptyline (P = 0.017). There was no 
statistical association present between any of 
the demographic and diagnostic variables, pain 
characteristics, medical comorbidities or other 
concurrent medications with the relief experienced 
by the participants following nerve block. These 
results are summarised in Tables 5 and 6.
Discussion
The purpose of this study was to evaluate the 
effectiveness of nerve blocks in the management 
of breakthrough HNC-associated trigeminal or 
cervical neuropathic pain disorders. Among the 
27 participants enrolled in this retrospective study, 
81.5% had 75% or more relief in symptoms for at 
least 48 hours, which on average lasted for 6.1 
weeks. A statistically significant association was 
found between the effectiveness of nerve blocks 
and concurrent use of amitriptyline.
Regional nerve blocks have been shown to be 
effective in the management of pain associated 
with migraine and cluster headache disorders, 
trigeminal and occipital neuralgias, trigeminal 
neuropathic pain disorders and neuropathic 
Table 3: Summary of pain characteristics of the 





Pain score Pre-procedure 6.85±2.54
Origin of pain Tumour related 81.5% (22)
Tumour and treatment 
related
18.5% (5)
Pain laterality Unilateral 70.4% (19)
Distribution of 
pain
Ophthalmic division 3.7% (1)
Maxillary division 18.5% (5)
Mandibular division 63.0% (17)














Other (electric, shooting) 14.8% (4)





Pain score Immediately post-pro-
cedure
0.26±1.02 
Relief in  
symptoms
More than 48 hours 81.5% (22)
1 week or more 74.1% (20)
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pain conditions affecting the lower extremities. 
However, there are no studies, to the best of our 
knowledge, which evaluate the effectiveness 
of local nerve blocks in the management of 
breakthrough pain in HNC-associated neuropathic 
pain disorders. In the present study, 81.5% of 
patients had significant relief in symptoms for 
nerve blocks. This relief continued beyond 1 
month for nearly 60% of the participants. Similar 
observations have been reported by investigators 
who have conducted nerve blocks for the 
management of primary headache disorders and 
Table 5: Breakdown of demographic and diagnostic characteristics of the study population based on response 
to nerve blocks
Study characteristic Category Significant improvement P-value
Yes No
Age (years) Mean 43.23±13.08 49.80±12.30 0.34
Gender Male 88.9% (16) 11.1% (2) 0.30
Cancer type Squamous cell carcinoma 82.6% (19) 17.4% (4) 1.00
Metastasis 87.5% (14) 12.5% (2) 0.37
Prior surgical intervention 84.6% (11) 15.4% (2) 1.00
Prior radiotherapy 87.5% (21) 12.5% (3) 0.08
Prior chemotherapy 87.5% (21) 12.5% (3) 0.08
Concurrent radiotherapy 50% (1) 50% (1) 0.34
Concurrent chemotherapy 78.6% (11) 21.4% (3) 1.00
Primary tumour site Alveolar mucosa 100% (11) - 0.06
Tongue 60% (3) 40% (2) 0.22
Buccal mucosa 75% (3) 25% (1) 1.00
Parotid gland 75% (3) 25% (1) 1.00
Other (nasopharyngeal, external auditory canal and 
hard palate)
83.3% (5) 16.7% (1) 1.00
Table 6: Breakdown of the pain characteristics of the study population based on response to the nerve blocks
Study characteristic Category Significant improvement P-value
Yes No
Pain score Pre-procedure 6.82±2.56 7.00±2.74 1.00
Origin of pain Tumour related 81.8% (18) 18.2% (4) 1.00
Tumour and treatment related 80% (4) 20% (1) 1.00
Pain laterality Unilateral 78.9% (15) 21.1% (4) 1.00
Distribution of pain Ophthalmic division 100% (1) - 1.00
Maxillary division 80% (4) 20% (1) 1.00
Mandibular division 82.4% (14) 17.6% (3) 1.00
Cervical nerve (C2-4) distribution 87.5% (14) 12.5% (2) 0.37
Quality of pain Burning 87.5% (14) 12.5% (2) 0.37
Dull ache 81.2% (13) 18.8% (3) 1.00
Stabbing 68.8% (11) 31.2% (5) 0.06
Throbbing 100% (6) - 0.56
Sharp 50% (3) 50% (3) 0.06
Other (electric, shooting) 75% (3) 25% (1) 1.00
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trigeminal neuropathic pain disorders of non-
cancerous origin.[11,14,15]
The mechanism of the prolonged analgesic 
response of a nerve block longer than the 
anaesthetic effect is unknown. HNC-associated 
pain is thought to be generated and sustained 
by the continuous activation of nociceptors by 
chemical mediators released by the tumour, 
such as endothelin-I, nerve growth factor and 
proteases and protease-activated receptors.[2,3] 
This continuous activation reduces the threshold 
of local nociceptors and increases the receptive 
field of activation (peripheral sensitisation), 
engages silent nociceptors and increases the 
excitability of the nociceptive neurons within the 
nervous system (central sensitisation).[3,19] Given 
that local anaesthesia blocks regional nociceptors 
and neurons from carrying any signals to 
the central nervous system, this reduction in 
nociceptive traffic may allow wind-down of 
the peripheral and central sensitisation, which 
would clinically result in a prolonged analgesic 
response.[10]
In the present study, significant relief in symptoms 
following a nerve block was statistically associated 
with the concurrent use of amitriptyline. These 
findings corroborate the reports from prior 
studies which have suggested amitriptyline to 
be effective in the management of neuropathic 
pain disorders of both oncologic and non-
oncologic origin.[20-23] While the mechanism of 
the action of amitriptyline in the management 
of neuropathic pain is not fully understood, it is 
known to block the reuptake of serotonin and 
norepinephrine neurotransmitters, which are 
involved in the process of pain transmission and 
pain perception, respectively.[24] Similarly, animal-
based investigations on the spinal trigeminal 
nucleus have suggested that amitriptyline induces 
segmental inhibition by preventing excessive firing 
of the wide dynamic neurons, which play a key role 
in the process of sensitisation.[25] Thus, it appears 
that amitriptyline synergises the analgesic response 
of the nerve blocks. Of note, the mechanism of 
the analgesic response of amitriptyline is likely to 
differ from the antidepressant action, particularly 
because analgesic effects of amitriptyline are 
usually achieved at lower dosages than the onset 
of any antidepressant effects. Similarly, prior 
studies have shown that there is no correlation 
between the effects of tricyclic antidepressants 
on mood and pain, and tricyclic antidepressants 
produce analgesia in participants with and without 
depression.[26]
A possible limitation of this study is due to its 
retrospective nature. Such studies have a low quality 
in the hierarchy of evidence due to the risk of recall 
and reporting bias and thus have a strong tendency 
to form positive association or magnification 
of the positive responses. Nevertheless, in the 
present investigation, data were extracted from 
the electronic hospital information system, which 
reduced the likelihood of bias. Likewise, patient 
records from other medical providers were 
reviewed to corroborate the information that 
was extracted from the follow-up clinical visits. 
Furthermore, in this study, we have used stringent 
criteria for defining a successful outcome to reduce 
the risk of forming spurious associations. This is the 
first study that has evaluated the efficacy of using 
nerve blocks in the management of trigeminal or 
cervical neuropathic pain associated with HNC. 
Nonetheless, these results need to be interpreted 
with caution and necessitate replication. Future 
trials with a randomised placebo or control study 
design are advised.
Local anaesthetic blocks, as an adjunctive treatment, 
can provide significant relief in breakthrough pain 
in patients with HNC-associated trigeminal and 
cervical neuropathic pain. However, there is no 
consistency in how long this relief may last. In 
addition, the beneficial response of nerve blocks 
was found to be more common in patients that 
were concurrently using amitriptyline.
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